TPBG
VRTX icon

Turning Point Benefit Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Turning Point Benefit Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24
Closed -$10.9K – 777
2025
Q4 		$10.9K Buy
24
+23
+2,300% +$9.91K 0.01% 239
2025
Q3 		$404 Buy
+1
New +$418 ﹤0.01% 535

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Turning Point Benefit Group's VRTX Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 24 shares — an estimated $10.9K sold.

Turning Point Benefit Group first reported a position in VRTX in Q3 2025 and held it in 2 quarters. The position peaked at $10.9K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 24 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.9K.
  • Turning Point Benefit Group first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Vertex Pharmaceuticals position peaked at $10.9K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.